Evaluation Component | Clinic-Level Measures |
---|---|
Clinically-Relevant Outcomes | |
EHR-based Measures (aggregate clinic-level data) | |
Treatment Agreement | Percent of eligible patientsa with signed treatment agreement in the past 12 months. |
Urine Drug Testing | Percent of eligible patientsa with the health system-recommended urine drug testing completed in the past 12 months. |
Opioid Therapy Risk Assessment | Percent of eligible patientsa with documented screening using the health system-recommended D.I.R.E. opioid misuse risk tool. |
Depression Screening | Percent of eligible patientsa with documented screening using the health system-recommended PHQ-2 or − 9 depression screening tool. |
Co-prescription of Opioids and Benzodiazepinesb | Percent of eligible patientsa with presence of active prescriptions for both opioids and benzodiazepines. |
PDMP Check | Percent of eligible patientsa with documented PDMP database check in the past 12 months. |
Process Measures (aggregate clinic-level data) | |
Clinic Team Surveys | Pre- and post-participation surveys will elicit: 1) ordinal responses as well as semi-qualitative comments to questions about current practice patterns; 2) comfort level with selected aspects of care for patients with opioid-treated chronic pain; 3) usefulness of the QI intervention components (post-participation). |
Clinic Team Member Participation in the Intervention Components | Percent of clinicians and clinical staff per clinic who: - participated in the academic detailing session - enrolled in and completed each of the two online educational modules - participated in the practice facilitation sessions |
Data from Practice Facilitators | Practice facilitator notes and experiences will enable identification of themes relevant to the implementation of the opioid policy (barriers and facilitators). |